2013-09-10 11:02:24 - New Pharmaceuticals market report from Global Markets Direct: "Pneumonia - Pipeline Review, H2 2013"
Global Markets Direct's, 'Pneumonia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pneumonia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pneumonia. Pneumonia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Full Report Details at
- www.fastmr.com/prod/675243_pneumonia_pipeline_review_h2_2013.asp ..
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for
the indicated disease.
* A snapshot of the global therapeutic scenario for Pneumonia.
* A review of the Pneumonia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Pneumonia pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.
Reasons to Get this Report
* Identify and understand important and diverse types of therapeutics under development for Pneumonia.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Pneumonia pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Companies Mentioned in this Report: Shionogi & Co., Ltd., Sanofi-Aventis, AstraZeneca PLC, Biotest AG, Dainippon Sumitomo Pharma Co., Ltd., Rib-X Pharmaceuticals, Inc., Cubist Pharmaceuticals, Inc., Toyama Chemical Co. Ltd, Wockhardt Limited, Paratek Pharmaceuticals, Inc., Bayer AG, Basilea Pharmaceutica Ltd., Flamel Technologies S.A., Dongwha Pharm Co., Ltd., LTT Bio-Pharma Co., Ltd., Synairgen plc, Mucosis B.V., Aridis Pharmaceuticals LLC, aRigen Pharmaceuticals, Inc., Sinovac Biotech Ltd., KaloBios Pharmaceuticals, Inc., Ancora Pharmaceuticals Inc., KYORIN Pharmaceutical Co., Ltd., Trius Therapeutics, Inc., Tetraphase Pharmaceuticals Inc., TaiGen Biotechnology Co., Ltd., Savara, Inc., Pulmotect, Inc., Durata Therapeutics Inc., APEPTICO Forschung und Entwicklung GmbH
Partial Table of Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
An Overview of Pipeline Products for Pneumonia
Pneumonia Therapeutics under Development by Companies
Pneumonia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Discovery and Pre-Clinical Stage Products
Pneumonia Therapeutics - Products under Development by Companies
Pneumonia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Pneumonia Therapeutics Development
Shionogi & Co., Ltd.
Dainippon Sumitomo Pharma Co., Ltd.
Rib-X Pharmaceuticals, Inc.
Cubist Pharmaceuticals, Inc.
Toyama Chemical Co. Ltd
Paratek Pharmaceuticals, Inc.
Basilea Pharmaceutica Ltd.
Flamel Technologies S.A.
Dongwha Pharm Co., Ltd.
LTT Bio-Pharma Co., Ltd.
Aridis Pharmaceuticals LLC
aRigen Pharmaceuticals, Inc.
Sinovac Biotech Ltd.
KaloBios Pharmaceuticals, Inc.
Ancora Pharmaceuticals Inc.
KYORIN Pharmaceutical Co., Ltd.
Trius Therapeutics, Inc.
Tetraphase Pharmaceuticals Inc.
TaiGen Biotechnology Co., Ltd.
Durata Therapeutics Inc.
APEPTICO Forschung und Entwicklung GmbH
Pneumonia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
amikacin - Drug Profile
dalbavancin - Drug Profile
cethromycin - Drug Profile
omadacycline tosylate - Drug Profile
brilacidin - Drug Profile
PC-SOD - Drug Profile
pafuramidine - Drug Profile
AR-401 - Drug Profile
AR-101 - Drug Profile
AR-301 - Drug Profile
PAC-G31P - Drug Profile
Gyrase Program - Drug Profile
KRP-109 - Drug Profile
tedizolid phosphate - Drug Profile
tedizolid phosphate - Drug Profile
zabofloxacin - Drug Profile
nemonoxacin - Drug Profile
Full Table of Contents is available at:
About Global Markets Direct
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.